ETR:EVT - Evotec Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
€20.01 +2.27 (+12.80 %)
(As of 11/18/2018 01:09 PM ET)
Previous Close€20.01
Today's Range€19.37 - €20.10
52-Week Range€7.91 - €22.50
Volume2.06 million shs
Average Volume1.36 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services, as well as absorption, distribution, metabolism, excretion, and toxicity services. The company is also involved in investing and developing proprietary assets, including early-stage discovery programs, as well as advanced drug candidates in the areas of diabetes and diabetic complications, inflammatory diseases, neuroscience, oncology, and pain and anti-infective. It has a strategic drug discovery and development partnership with Celgene Corporation to identify therapeutics in oncology; and a strategic alliance with Novo Nordisk A/S to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities; collaboration with Sanofi to develop LAB031, which accelerates drug discovery across various therapeutic areas; and a strategic research collaboration with Almirall, S.A. to discover and develop first-in-class therapeutics in the field of dermatology diseases, as well as strategic collaboration agreement with Centogene AG. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany.

Receive EVT News and Ratings via Email

Sign-up to receive the latest news and ratings for EVT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange ETR
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolETR:EVT
Previous Symbol
CUSIPN/A
Phone+49-40-560810

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees2,268
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable

Evotec (ETR:EVT) Frequently Asked Questions

What is Evotec's stock symbol?

Evotec trades on the ETR under the ticker symbol "EVT."

What price target have analysts set for EVT?

3 equities research analysts have issued 12 month price objectives for Evotec's stock. Their forecasts range from €20.00 to €26.00. On average, they expect Evotec's stock price to reach €22.33 in the next twelve months. This suggests a possible upside of 11.6% from the stock's current price. View Analyst Price Targets for Evotec.

What is the consensus analysts' recommendation for Evotec?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evotec in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evotec.

Has Evotec been receiving favorable news coverage?

News coverage about EVT stock has trended positive on Sunday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Evotec earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are some of Evotec's key competitors?

Who are Evotec's key executives?

Evotec's management team includes the folowing people:
  • Dr. Werner Lanthaler, CEO & Member of Management Board (Age 50)
  • Mr. Enno Spillner, CFO & Member of Management Board (Age 48)
  • Dr. Mario Polywka, COO & Member of Management Board (Age 55)
  • Dr. Cord Dohrmann, Chief Scientific Officer & Member of Management Board (Age 54)
  • Ms. Anja Bosler, Principal Accounting Officer and Sr. VP of Group Accounting

What is Evotec's stock price today?

One share of EVT stock can currently be purchased for approximately €20.01.

What is Evotec's official website?

The official website for Evotec is https://www.evotec.com/.

How can I contact Evotec?

Evotec's mailing address is Essener Bogen 7, HAMBURG, 22419, Germany. The company can be reached via phone at +49-40-560810.


MarketBeat Community Rating for Evotec (ETR EVT)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  114 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  224
MarketBeat's community ratings are surveys of what our community members think about Evotec and other stocks. Vote "Outperform" if you believe EVT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel